# Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

> **NCT04570943** · PHASE2 · RECRUITING · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 103 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Adenocarcinoma

## Interventions

- **COMBINATION_PRODUCT:** Gabrinox
- **RADIATION:** MRI-GUIDED STEREOTACTIC RADIOTHERAPY

## Key facts

- **NCT ID:** NCT04570943
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-16
- **Primary completion:** 2028-01
- **Final completion:** 2030-06
- **Target enrollment:** 103 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04570943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04570943, "Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04570943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*